The Walt Disney Company (NYSE:DIS) is one of the stocks Jim Cramer recently talked about. During the episode, a caller asked if the stock is a buy, sell, or hold. In response, Cramer said: “I think Disney’s a hold, and I say that because… I think it’s too cheap to give away, but I felt higher prices that I just wanted to say, you know what? This thing could go to $95. Maybe I take a look at it there, but it doesn’t have the earnings. It had a quarter that everyone thought was good, and it was just hated. ...

With strong three-month performance and significant upside potential, Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) secures a spot on our list of the 12 hot penny stocks to invest in right now. Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements A dose bottle of the medication is in the medical tech's hand On November 12, 2025, The Fly reported that Barclays reduced its price target on Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) from $12 to $11, whi ...

Core Insights - Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) has shown strong performance, with a 14.48% increase in stock price to $3.40, marking its fourth consecutive day of gains as investors react positively to its third-quarter earnings [1][3]. Financial Performance - Petco reported a net income of $9.3 million for the third quarter, a significant turnaround from a net loss of $16.67 million in the same period last year [2]. - Operating income surged by 634%, reaching $29.2 million compared to $3.98 million year-on-year [2]. - Net sales decreased by 3.3% to $1.46 billion from $1.51 billion, aligning with the company's expectations [2]. Future Outlook - For the full year, Petco anticipates a revenue decline of 2.5% to 2.8% but has raised its adjusted EBITDA guidance to a range of $395 million to $397 million, up from the previous range of $385 million to $395 million [4]. - In the fourth quarter, net sales are expected to dip by low single digits, while adjusted EBITDA is projected to be between $93 million and $95 million [4]. Strategic Focus - The CEO of Petco emphasized the company's commitment to profitability and the ongoing multi-phased transformation, aiming to rebuild the economic model as a foundation for future growth in fiscal 2026 [3].

We recently published 10 Small Stocks with Mighty Gains. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the top-performing stocks on Wednesday. Ironwood Pharmaceuticals soared by 23.32 percent on Wednesday to end at $3.86 apiece as investors cheered the new price set by the Health Department for its bowel treatment, which fell in line with its expectations. In a regulatory filing, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) said that the US Department of Health and Human Services released the ma ...

Core Insights - Long Cast Advisers reported a cumulative net return improvement of 4% in Q3 2025, with a total cumulative return of 266% net of fees since inception in November 2015, translating to a 14% CAGR [1] Company Overview: Quest Resource Holding Corporation (NASDAQ:QRHC) - Quest Resource Holding Corporation provides waste and recycling services and is headquartered in The Colony, Texas [2] - The stock experienced a one-month return of 29.66%, but has lost 73.82% of its value over the past 52 weeks, closing at $1.88 per share with a market capitalization of $39.236 million on November 27, 2025 [2] Performance Analysis - Year-to-date, Quest Resource Holding Corporation has been a significant detractor for Long Cast Advisers' portfolio, leading to its removal from the top-five holdings [3] - The company reported revenue of $63.3 million in Q3 2025, which is a 13% decrease compared to Q3 2024 but a 6.4% increase from Q2 2025 [4] Management and Valuation Concerns - The company has improved management and operational processes, making it a more reasonable investment despite its past performance [3] - There is a notable discrepancy between $80 million in goodwill and a $35 million market capitalization, which is expected to trigger an annual impairment test [3] Hedge Fund Interest - Quest Resource Holding Corporation is not among the 30 most popular stocks among hedge funds, with only 8 hedge fund portfolios holding the stock at the end of Q3 2025, down from 12 in the previous quarter [4]

Core Insights - Alger Small Cap Focus Fund's third-quarter 2025 investor letter indicates that U.S. equity markets experienced significant growth, with the S&P 500 Index rising by 8.12% due to improving economic conditions, solid corporate earnings, and expectations for monetary easing [1] - The fund's class A shares underperformed compared to the Russell 2000 Growth Index during the same period [1] Company Overview - Tutor Perini Corporation (NYSE:TPC) is a leading construction company that provides a wide range of services including general contracting, construction management, and design-build services to both private and public sector clients globally [3] - The company reported a stock price of $67.56 per share as of November 27, 2025, with a one-month return of -0.19% and a remarkable 147.93% increase in value over the last 52 weeks [2] Financial Performance - Tutor Perini Corporation's shares positively contributed to the fund's performance in the quarter following strong second-quarter results and an increase in full-year 2025 earnings guidance [3] - Management anticipates a significant increase in earnings for 2026, supported by infrastructure spending and improved project execution, which has enhanced investor confidence [3] Hedge Fund Interest - Tutor Perini Corporation is not among the 30 most popular stocks among hedge funds, with 36 hedge fund portfolios holding the stock at the end of the third quarter, up from 31 in the previous quarter [4] - While the company shows potential as an investment, the analysis suggests that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Insights - The Alger Small Cap Focus Fund's third-quarter 2025 investor letter indicates that U.S. equity markets experienced significant growth, with the S&P 500 Index rising by 8.12% due to improving economic conditions, solid corporate earnings, and expectations for monetary easing [1] - The fund's class A shares underperformed compared to the Russell 2000 Growth Index during the same period [1] Company Overview: Portillo's Inc. (NASDAQ:PTLO) - Portillo's Inc. is a fast-casual restaurant chain known for Chicago-style hot dogs and Italian beef sandwiches, operating company-owned locations across the U.S. [3] - The stock of Portillo's Inc. experienced a one-month return of -2.80% and a significant decline of 54.44% over the past 52 weeks, closing at $5.21 per share with a market capitalization of $374.767 million as of November 27, 2025 [2] Financial Performance - In the third quarter of 2025, Portillo's Inc. reported revenue of $181.4 million, which is an increase of $3.2 million compared to Q3 2024 [4] - The company reported weaker-than-expected fiscal second-quarter results, leading management to reduce full-year guidance for same-restaurant sales due to softer traffic and underperformance at newer locations [3] Investment Sentiment - Portillo's Inc. is not among the 30 most popular stocks among hedge funds, with 18 hedge fund portfolios holding the stock at the end of Q3 2025, down from 26 in the previous quarter [4] - While the potential for Portillo's Inc. as an investment is acknowledged, the fund suggests that certain AI stocks may offer greater upside potential and less downside risk [4]

Group 1 - Sanofi is considered one of the best low volatility large cap stocks to invest in, with a Buy rating maintained by Deutsche Bank analyst Emmanuel Papadakis and a price target set at €110 [1] - Sanofi announced the approval of Dupixent (dupilumab) by the European Commission for treating moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and above who have inadequate response to H1 antihistamines [2][3] - Dupixent is recognized as the first targeted medicine approved in the EU for chronic spontaneous urticaria in over a decade, based on phase 3 studies showing significant reduction in itch and hives at 24 weeks compared to placebo [3] Group 2 - Sanofi operates in three segments: Pharmaceuticals, Consumer Healthcare, and Vaccines, focusing on research, production, and distribution of pharmaceutical products [4]

Core Viewpoint - The Progressive Corporation (NYSE:PGR) is highlighted as a strong low volatility investment option, with an increased price target of $260 from $247 by BMO Capital analyst Michael Zaremski while maintaining a Market Perform rating on the shares [1][2]. Financial Performance - The Progressive Corporation reported $7.002 billion in net premiums written in October 2025, an increase from $6.578 billion in the same month last year, indicating growth in the company's premium income [3]. - The net income for October 2025 rose to $846 million, a significant increase of 107% compared to $408 million in October 2024 [3]. Share Repurchase Strategy - In October, The Progressive Corporation repurchased a modest $24 million in shares, but it is anticipated that the company will engage in repurchases in the low billions through 2026 if its P/E multiple remains below 15 times [2]. Company Overview - The Progressive Corporation operates as an insurance holding company, providing residential property insurance, personal and commercial auto insurance, and other specialty property-casualty insurance and related services through its Personal Lines, Commercial Lines, and Property segments [4]. Market Conditions - The company has maintained consistently excellent margins, with double-digit auto inflationary pressures showing signs of deceleration from all-time highs [3].

Core Viewpoint - Atlas Energy Solutions Inc. (NYSE:AESI) has experienced a significant decline in share price due to negative analyst sentiment and disappointing financial results [1][3][5]. Company Performance - The share price of Atlas Energy Solutions fell by 5.55% from November 19 to November 26, 2025, making it one of the worst-performing energy stocks during that week [1]. - The company engages in the production, processing, and sale of mesh and sand used as proppants in the well completion process, primarily in the Permian Basin of West Texas and New Mexico [2]. Analyst Downgrades - Goldman Sachs analyst Ati Modak downgraded AESI from 'Neutral' to 'Sell' and reduced the price target from $12 to $8, citing concerns over FY 2026 growth and forecasting EBITDA to be around 10% below consensus due to lower sand prices and slower volume growth [3]. - Piper Sandler also lowered its price target from $12 to $10 while maintaining a 'Neutral' rating [4]. - Barclays downgraded AESI from 'Equal Weight' to 'Underweight' and trimmed its price target from $11 to $7 [4]. Financial Results - Atlas Energy Solutions reported disappointing third-quarter results, falling short of both earnings and revenue expectations, which contributed to the bearish analyst sentiment [5].